Ratan Capital Management LP acquired a new position in Solventum Corporation (NYSE:SOLV – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $1,543,000. Solventum accounts for about 0.5% of Ratan Capital Management LP’s portfolio, making the stock its 29th biggest position.
Other institutional investors have also added to or reduced their stakes in the company. CrossGen Wealth LLC bought a new position in Solventum during the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum in the 3rd quarter worth approximately $25,000. Clearstead Trust LLC boosted its stake in shares of Solventum by 61.0% in the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares during the last quarter. CYBER HORNET ETFs LLC bought a new stake in shares of Solventum in the 2nd quarter valued at $28,000. Finally, Modus Advisors LLC acquired a new stake in shares of Solventum during the fourth quarter worth $30,000.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on SOLV shares. BMO Capital Markets started coverage on shares of Solventum in a research note on Wednesday, July 8th. They set a “market perform” rating and a $81.00 target price for the company. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, August 22nd. KeyCorp increased their price target on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Wedbush lifted their price objective on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Finally, UBS Group boosted their price objective on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.64.
Solventum Stock Performance
Shares of SOLV stock opened at $91.02 on Friday. The firm has a 50 day moving average of $82.46 and a 200-day moving average of $75.55. The company has a market cap of $15.49 billion, a price-to-earnings ratio of 11.13, a price-to-earnings-growth ratio of 1.17 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $92.71.
Solventum (NYSE:SOLV – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. Solventum’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities analysts forecast that Solventum Corporation will post 7.22 earnings per share for the current year.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Featured Stories
- Five stocks we like better than Solventum
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
